StockGuide AI - assistant for market research

Biotech Sector Remains Attractive to Investors Following Significant Recovery

07/22/2026, 01:37 PM investing review biotech healthcare

Investors in the biotechnology sector are maintaining a positive outlook following significant gains this year, driven by factors such as potential mergers and acquisitions and a recovery in clinical trials. The performance of key ETFs and specific companies, like Revolution Medicines, highlights the sector's resilience and growth potential.

Axiom Biosciences Plans to List in Hong Kong Before U.S. IPO Amid Changing Biotech Landscape

07/21/2026, 05:37 PM economy announcement biotech

Axiom Biosciences plans to go public in Hong Kong in 2027, marking a significant shift as it seeks to tap into Asia's biotech investment landscape, which has become increasingly attractive amid a challenging fundraising environment in the U.S.

Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion in Cash

07/19/2026, 07:31 PM announcement biotech

Samsung Biologics has announced a significant all-cash acquisition of PolyPeptide Group for $1.8 billion, marking a historic deal in South Korea's biopharmaceutical sector. This move aims to enhance Samsung's portfolio in the rapidly growing peptide therapeutics market, particularly in obesity treatments.

Nvidia Expands Physical AI Ecosystem in Japan with New Cosmos 3 Edge Model

07/16/2026, 04:36 AM economy announcement ai biotech

Nvidia's introduction of the Cosmos 3 Edge AI model marks a significant expansion into Japan's physical AI market, highlighting the company's strategic partnerships with local industrial giants and its focus on healthcare and biotechnology applications.

Analysts highlight IQVIA (IQV) and Danaher (DHR) as leading biotech stocks poised for recovery

07/14/2026, 09:38 AM investing review Analysts: analysts biotech healthcare

The biotechnology sector, which has faced significant challenges in recent years, is showing signs of recovery, presenting potential investment opportunities in companies like IQVIA, Danaher, and Vertex Pharmaceuticals. This shift is driven by stabilizing funding conditions, increased clinical trial activity, and the need for pharmaceutical companies to innovate as patent expirations loom.

Analysts Truist upgraded Biogen (BIIB) to Buy and raised target price to $235 on positive drug trial data expectations

07/13/2026, 06:37 AM investing rating_growth Analysts: analysts, Truist biotech

Truist Securities has upgraded Biogen to 'buy' and raised its price target, anticipating positive data from upcoming trials for its Alzheimer's treatment, which could significantly boost the company's stock.

Abivax Secures $920 Million Funding to Prepare for Independent U.S. Launch of Bowel Disease Drug, CEO Marc de Garidel Tells CNBC

07/10/2026, 03:36 AM business announcement biotech

Abivax has successfully raised $920 million, enabling it to independently pursue the U.S. launch of its bowel disease drug, obefazimod, without relying on a potential acquisition. This funding positions the company to finance operations through 2029 and address recent investor concerns regarding the drug's safety and efficacy.

Analysts recommend buying Biogen (BIIB) shares as breakout signals bullish trend

07/02/2026, 10:36 AM investing recommendation Analysts: analysts biotech

Investors should consider Biogen (BIIB) as a promising opportunity in the biotech sector, given its recent technical breakout and potential for significant upside, while also keeping an eye on the broader Bio-Tech ETF (XBI) for safer exposure.

Abivax (ABVX) shares surge 25% following positive data on experimental bowel disease treatment

06/30/2026, 12:35 AM business stock_growth biotech

Abivax's stock surged 25% following the release of new clinical trial data for its experimental drug obefazimod, which alleviated concerns over cancer risks associated with the treatment. This rebound is significant for investors, as it indicates renewed confidence in the company's prospects after a prior steep decline.

Analysts Carter Worth recommends buying Incyte (INCY) shares as it breaks out of a seven-month range

06/26/2026, 11:37 AM investing recommendation Analysts: analysts, Carter Worth biotech

Incyte, a biopharmaceutical company, is poised for a potential breakout after being stagnant for seven months, with analysts suggesting a bullish outlook as it aims to surpass the $125 mark.

Topic: biotech